Home Cart Sign in  
Chemical Structure| 529488-28-6 Chemical Structure| 529488-28-6

Structure of Genz-644282
CAS No.: 529488-28-6

Chemical Structure| 529488-28-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Genz-644282 is a non-camptothecin inhibitor of topoisomerase I with potential antineoplastic activity (IC50=1.2 nM).

Synonyms: Genz-644282

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Genz-644282

CAS No. :529488-28-6
Formula : C22H21N3O5
M.W : 407.42
SMILES Code : O=C1N(CCNC)C2=C(C=NC(C2=C3)=CC4=C3OCO4)C5=CC(OC)=C(OC)C=C15
Synonyms :
Genz-644282
MDL No. :MFCD25976816
InChI Key :BAORCAMWLWRZQG-UHFFFAOYSA-N
Pubchem ID :10294813

Safety of Genz-644282

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Related Pathways of Genz-644282

DNA

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
GL261 murine glioma cells 1 or 100 nM 6 hours To assess whether The-0504 induces DNA double-strand breaks, results showed that γH2AX expression increases up to 2-fold compared to control Cell Death Dis. 2024 Apr 13;15(4):262
U-87 MG human glioblastoma cells 1-100 nM 48 hours To assess the effect of The-0504 on cell viability, results showed that The-0504 decreases cell viability in a concentration-dependent fashion with an IC50 of about 100 nM Cell Death Dis. 2024 Apr 13;15(4):262
GL261 murine glioma cells 1-100 nM 48 hours To assess the effect of The-0504 on cell viability, results showed that The-0504 decreases cell viability in a concentration-dependent fashion with an IC50 of about 100 nM Cell Death Dis. 2024 Apr 13;15(4):262
MiaPaca2 cells 1 μM 6 hours To assess the expression of the DNA double-strand break marker γH2AX. The-0504 induced more pronounced and persistent γH2AX phosphorylation compared to free Genz-644282. Heliyon. 2023 Oct 6;9(10):e20770
CPT-K5 cells (carrying D533G mutation in TOP1 gene) 0.1 μM and 1 μM 4 and 24 hours Evaluated cytotoxicity of Genz-644282 against CPT-resistant cell lines, finding Genz only slightly induced DSB formation at 1 μM, indicating D533G mutation confers Genz resistance. J Exp Clin Cancer Res. 2021 Feb 10;40(1):63
CEM/C2 cells (carrying N722S mutation in TOP1 gene) 1 μM 4 and 24 hours Evaluated cytotoxicity of Genz-644282 against CPT-resistant cell lines, finding Genz effectively induced DSB formation while CPT did not. J Exp Clin Cancer Res. 2021 Feb 10;40(1):63
SV40-transformed MRC5 cells 1 μM 4 and 24 hours Investigated the mechanism of Genz-644282-induced double-strand breaks (DSBs) formation, finding early response dependent on TOP1 function but not MUS81–EME1/2 function, while late response required both functions. J Exp Clin Cancer Res. 2021 Feb 10;40(1):63

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6N mice GL261 glioma model Intranasal or intravenous 0.3 mg/kg or 0.9 mg/kg (intranasal); 2.0 mg/kg (intravenous) Every two days for 2 weeks (six times) To evaluate the effect of The-0504 on glioma volume and survival rate, results showed that intranasal administration reduced tumor volume by more than 70%, intravenous administration reduced it by 53%, and intranasal administration significantly improved survival rate Cell Death Dis. 2024 Apr 13;15(4):262
Mice Human tumor xenograft models Intravenous 1.9 mg/kg, 2.0 mg/kg, 1.5 mg/kg, 3.0 mg/kg, 6.0 mg/kg Twice or once a week for three weeks To evaluate the anti-tumor activity of The-0504. Significant anti-tumor effects were observed in most models, including complete tumor regression. Heliyon. 2023 Oct 6;9(10):e20770

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.45mL

0.49mL

0.25mL

12.27mL

2.45mL

1.23mL

24.54mL

4.91mL

2.45mL

References

 

Historical Records

Categories